A phase 1 clinical trial found that Landos Biopharma's Crohn's disease and ulcerative colitis treatment, BT-11, was well-tolerated with no dose-limiting toxicities or detectable systemic immunosuppression.
What you should know:
1. Researchers tested BT-11 in 70 patients as either a single-ascending dose or as a seven-day multiple-ascending dose.
2. Fecal concentrations of BT-11 were 6,000 times higher than maximum plasma concentrations. Researchers said the increased concentrations mirrored what they observed in preclinical animal tests.
3. Landos will explore the seven-day, 14 milligram dosage in a phase 2 clinical trial.
More articles on gastroenterology:
3 things to know about outpatient cervical disc replacement
10 things to know about spine surgery for ASCs in 2019
Outpatient revision minimally invasive lumbar decompression: 4 notes on ASC vs. HOPD